Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Ladstein, Rita G ^a   Bachmann, Ingeborg M ^a,b   Straume, Oddbjørn ^a   Akslen, Lars A ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H3; KI 67 ANTIGEN; MINICHROMOSOME MAINTENANCE PROTEIN 4; MITOSIN; PHOSPHOHISTONE H3; TUMOR MARKER; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; CELL CYCLE PROTEIN; CENTROMERE PROTEIN F; DNA BINDING PROTEIN; HISTONE; MCM4 PROTEIN, HUMAN; NONHISTONE PROTEIN; NUCLEAR PROTEIN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER INVASION; CANCER SIZE; CELL COUNT; CELL PROLIFERATION; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MELANOMA; MELANOMA CELL; MITOSIS; PROGNOSIS; SKIN NODULE; SKIN ULCER; TISSUE MICROARRAY; TUMOR NECROSIS; VASCULAR TUMOR; AGED; CANCER STAGING; CHEMISTRY; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; KAPLAN MEIER METHOD; MIDDLE AGED; MITOSIS INDEX; MORTALITY; NECROSIS; PATHOLOGY; PHOSPHORYLATION; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; SKIN TUMOR; UPREGULATION;

AGED; CELL CYCLE PROTEINS; CELL PROLIFERATION; CHI-SQUARE DISTRIBUTION; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA-BINDING PROTEINS; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; KI-67 ANTIGEN; MELANOMA; MICROFILAMENT PROTEINS; MIDDLE AGED; MITOTIC INDEX; NECROSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NUCLEAR PROTEINS; PHOSPHORYLATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SKIN NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 77950633109     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-140     Document Type: Article

References (52)

1. Beddingfield FC. The melanoma epidemic: res ipsa loquitur. Oncologist 2003, 8(5):459-465. 10.1634/theoncologist.8-5-459, 14530499.
2. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005, 365(9460):687-701.
3. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004, 351(10):998-1012. 10.1056/NEJMra041245, 15342808.
4. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001, 19(16):3622-3634.
5. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Kirkwood JM, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001, 19(16):3635-3648.
6. Barnhill RL, Katzen J, Spatz A, Fine J, Berwick M. The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma. J Cutan Pathol 2005, 32(4):268-273. 10.1111/j.0303-6987.2005.00310.x, 15769275.
7. Francken AB, Shaw HM, Thompson JF, Soong SJ, Accortt NA, Azzola MF, Scolyer RA, Milton GW, McCarthy WH, Colman MH, et al. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol 2004, 11(4):426-433. 10.1245/ASO.2004.07.014, 15070604.
8. Nagore E, Oliver V, Botella-Estrada R, Moreno-Picot S, Insa A, Fortea JM. Prognostic factors in localized invasive cutaneous melanoma: high value of mitotic rate, vascular invasion and microscopic satellitosis. Melanoma Res 2005, 15(3):169-177. 10.1097/00008390-200506000-00005, 15917698.
9. Gimotty PA, Van Belle P, Elder DE, Murry T, Montone KT, Xu X, Hotz S, Raines S, Ming ME, Wahl P, et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol 2005, 23(31):8048-8056. 10.1200/JCO.2005.02.0735, 16258103.
10. Azzola MF, Shaw HM, Thompson JF, Soong SJ, Scolyer RA, Watson GF, Colman MH, Zhang Y. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer 2003, 97(6):1488-1498. 10.1002/cncr.11196, 12627514.
11. Ross MI. Early-stage melanoma: staging criteria and prognostic modeling. Clin Cancer Res 2006, 12(7 Pt 2):2312s-2319s. 10.1158/1078-0432.CCR-05-2643, 16609051.
12. Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW. Immunohistochemical characteristics of melanoma. J Cutan Pathol 2008, 35(5):433-444. 10.1111/j.1600-0560.2007.00891.x, 18399807.
13. Straume O, Sviland L, Akslen LA. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res 2000, 6(5):1845-1853.
14. Hendzel MJ, Wei Y, Mancini MA, Van Hooser A, Ranalli T, Brinkley BR, Bazett-Jones DP, Allis CD. Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 1997, 106(6):348-360. 10.1007/s004120050256, 9362543.
15. Juan G, Traganos F, James WM, Ray JM, Roberge M, Sauve DM, Anderson H, Darzynkiewicz Z. Histone H3 phosphorylation and expression of cyclins A and B1 measured in individual cells during their progression through G2 and mitosis. Cytometry 1998, 32(2):71-77. 10.1002/(SICI)1097-0320(19980601)32:2<71::AID-CYTO1>3.0.CO;2-H, 9627219.
16. Hendzel MJ, Nishioka WK, Raymond Y, Allis CD, Bazett-Jones DP, Th'ng JP. Chromatin condensation is not associated with apoptosis. J Biol Chem 1998, 273(38):24470-24478. 10.1074/jbc.273.38.24470, 9733739.
17. Kim YJ, Ketter R, Steudel WI, Feiden W. Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas. Am J Clin Pathol 2007, 128(1):118-125. 10.1309/HXUNAG34B3CEFDU8, 17580279.
18. Takei H, Bhattacharjee MB, Rivera A, Dancer Y, Powell SZ. New immunohistochemical markers in the evaluation of central nervous system tumors: a review of 7 selected adult and pediatric brain tumors. Arch Pathol Lab Med 2007, 131(2):234-241.
19. Skaland I, Janssen EA, Gudlaugsson E, Klos J, Kjellevold KH, Soiland H, Baak JP. Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age. Mod Pathol 2007, 20(12):1307-1315. 10.1038/modpathol.3800972, 17917671.
20. Nasr MR, El-Zammar O. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol 2008, 30(2):117-122. 10.1097/DAD.0b013e3181624054, 18360113.
21. Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. Journal of the National Cancer Institute 2006, 98(7):472-482.
22. Bell SP, Dutta A. DNA replication in eukaryotic cells. Annu Rev Biochem 2002, 71:333-374. 10.1146/annurev.biochem.71.110601.135425, 12045100.
23. Tachibana KE, Gonzalez MA, Coleman N. Cell-cycle-dependent regulation of DNA replication and its relevance to cancer pathology. J Pathol 2005, 205(2):123-129. 10.1002/path.1708, 15643673.
24. Jaeger J, Koczan D, Thiesen HJ, Ibrahim SM, Gross G, Spang R, Kunz M. Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin Cancer Res 2007, 13(3):806-815. 10.1158/1078-0432.CCR-06-1820, 17289871.
25. Zhu X, Mancini MA, Chang KH, Liu CY, Chen CF, Shan B, Jones D, Yang-Feng TL, Lee WH. Characterization of a novel 350-kilodalton nuclear phosphoprotein that is specifically involved in mitotic-phase progression. Mol Cell Biol 1995, 15(9):5017-5029. 230749, 7651420.
26. O'Brien SL, Fagan A, Fox EJ, Millikan RC, Culhane AC, Brennan DJ, McCann AH, Hegarty S, Moyna S, Duffy MJ, et al. CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. Int J Cancer 2007, 120(7):1434-1443. 10.1002/ijc.22413, 17205517.
27. Clark GM, Allred DC, Hilsenbeck SG, Chamness GC, Osborne CK, Jones D, Lee WH. Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer. Cancer Res 1997, 57(24):5505-5508.
28. Gonzalez S, Klatt P, Delgado S, Conde E, Lopez-Rios F, Sanchez-Cespedes M, Mendez J, Antequera F, Serrano M. Oncogenic activity of Cdc6 through repression of the INK4/ARF locus. Nature 2006, 440(7084):702-706. 10.1038/nature04585, 16572177.
29. Foulkes WD, Flanders TY, Pollock PM, Hayward NK. The CDKN2A (p16) gene and human cancer. Mol Med 1997, 3(1):5-20. 2230107, 9132280.
30. Straume O, Akslen LA. Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma. Int J Cancer 1997, 74(5):535-539. 10.1002/(SICI)1097-0215(19971021)74:5<535::AID-IJC10>3.0.CO;2-5, 9355977.
31. Bachmann IM, Straume O, Akslen LA. Altered expression of cell cycle regulators Cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas. Int J Oncol 2004, 25(6):1559-1565.
32. Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP, Akslen LA. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 2006, 24(2):268-273. 10.1200/JCO.2005.01.5180, 16330673.
33. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970, 172(5):902-908. 10.1097/00000658-197011000-00017, 1397358, 5477666.
34. Clark WH, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969, 29(3):705-727.
35. Straume O, Akslen LA. Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol 2001, 159(1):223-235. 1850434, 11438469.
36. Bachmann IM, Ladstein RG, Straume O, Naumov GN, Akslen LA. Tumor necrosis is associated with increased alphavbeta3 integrin expression and poor prognosis in nodular cutaneous melanomas. BMC Cancer 2008, 8:362. 10.1186/1471-2407-8-362, 2631589, 19061491.
37. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998, 4(7):844-847. 10.1038/nm0798-844, 9662379.
38. Nocito A, Bubendorf L, Maria Tinner E, Suess K, Wagner U, Forster T, Kononen J, Fijan A, Bruderer J, Schmid U, et al. Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol 2001, 194(3):349-357. 10.1002/1096-9896(200107)194:3<349::AID-PATH887>3.0.CO;2-D, 11439368.
39. Straume O, Akslen LA. Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression. Am J Pathol 2002, 160(3):1009-1019. 1867162, 11891198.
40. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100(1):57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
41. Attis MG, Vollmer RT. Mitotic rate in melanoma: a reexamination. Am J Clin Pathol 2007, 127(3):380-384. 10.1309/LB7RTC61B7LC6HJ6, 17276944.
42. Gould Rothberg BE, Bracken MB, Rimm DL. Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2009, 101(7):452-474. 10.1093/jnci/djp038, 2720709, 19318635.
43. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000, 182(3):311-322. 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9, 10653597.
44. Frahm SO, Schubert C, Parwaresch R, Rudolph P. High proliferative activity may predict early metastasis of thin melanomas. Hum Pathol 2001, 32(12):1376-1381. 10.1053/hupa.2001.29658, 11774172.
45. Bossard C, Jarry A, Colombeix C, Bach-Ngohou K, Moreau A, Loussouarn D, Mosnier JF, Laboisse CL. Phosphohistone H3 labelling for histoprognostic grading of breast adenocarcinomas and computer-assisted determination of mitotic index. J Clin Pathol 2006, 59(7):706-710. 10.1136/jcp.2005.030452, 1860410, 16461563.
46. Tapia C, Kutzner H, Mentzel T, Savic S, Baumhoer D, Glatz K. Two mitosis-specific antibodies, MPM-2 and phospho-histone H3 (Ser28), allow rapid and precise determination of mitotic activity. Am J Surg Pathol 2006, 30(1):83-89. 10.1097/01.pas.0000183572.94140.43, 16330946.
47. Collett K, Eide GE, Arnes J, Stefansson IM, Eide J, Braaten A, Aas T, Otte AP, Akslen LA. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res 2006, 12(4):1168-1174. 10.1158/1078-0432.CCR-05-1533, 16489070.
48. Vekony H, Raaphorst FM, Otte AP, van Lohuizen M, Leemans CR, Waal I, Bloemena E. High expression of Polycomb group protein EZH2 predicts poor survival in salivary gland adenoid cystic carcinoma. J Clin Pathol 2008, 61(6):744-749. 10.1136/jcp.2007.054262, 18326020.
49. Kidani K, Osaki M, Tamura T, Yamaga K, Shomori K, Ryoke K, Ito H. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas. Oral Oncol 2009, 45(1):39-46. 10.1016/j.oraloncology.2008.03.016, 18619895.
50. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003, 22(20):5323-5335. 10.1093/emboj/cdg542, 213796, 14532106.
51. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419(6907):624-629. 10.1038/nature01075, 12374981.
52. Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 2008, 647(1-2):21-29.